Physician profile
Henry Gor
NPI 1386612307
$6,721.44
in general payments reported to CMS, 2019-2025
39 companies · $458 in 2025
The $458 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $545 · 2021: $1,388 · 2022: $1,733 · 2023: $1,256 · 2024: $748 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.95 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.31 | 2019-2024 | |
| Fujirebio Diagnostics, Incorporated | $724.94 | 2022 | |
| Mayne Pharma Commercial LLC | $698.67 | 2021-2025 | |
| Astellas Pharma US INC | $426.23 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $406.24 | 2019-2024 | Evenity |
| Exeltis, USA INC. | $386.18 | 2021-2024 | Slynd |
| Daiichi Sankyo INC. | $347.76 | 2019-2022 | |
| Lupin INC. | $341.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $295.95 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $291.46 | 2019-2025 | |
| Shield Therapeutics INC | $258.48 | 2022-2024 | |
| Avion Pharmaceuticals | $195.12 | 2019-2023 | Balcoltra |
| Coopersurgical, INC. | $149.43 | 2021 | |
| Organon LLC | $147.62 | 2021-2024 | Nexplanon |
| Myriad Women'S Health, INC. | $118.12 | 2023 | Myrisk |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Gor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.